CB1 receptor (cnr1_human)
FAMILY
Class A (Rhodopsin) Lipid receptors Cannabinoid receptors CB1 receptor
GENE
CNR1 (CNR)
ORGANISM
Human (Homo sapiens)
ALT. NAMES
Cannabinoid receptor 1, CB-R, CB1, CANN6
SOURCE
SWISSPROT
SEQUENCE
N-term | |||||||||
M
|
K
|
S
|
I
|
L
|
D
|
G
|
L
|
A
|
D
|
10 |
T
|
T
|
F
|
R
|
T
|
I
|
T
|
T
|
D
|
L
|
20 |
L
|
Y
|
V
|
G
|
S
|
N
|
D
|
I
|
Q
|
Y
|
30 |
E
|
D
|
I
|
K
|
G
|
D
|
M
|
A
|
S
|
K
|
40 |
L
|
G
|
Y
|
F
|
P
|
Q
|
K
|
F
|
P
|
L
|
50 |
T
|
S
|
F
|
R
|
G
|
S
|
P
|
F
|
Q
|
E
|
60 |
K
|
M
|
T
|
A
|
G
|
D
|
N
|
P
|
Q
|
L
|
70 |
V
|
P
|
A
|
D
|
Q
|
V
|
N
|
I
|
T
|
E
|
80 |
F
|
Y
|
N
|
K
|
S
|
L
|
S
|
S
|
F
|
K
|
90 |
E
|
N
|
E
|
E
|
N
|
I
|
Q
|
C
|
G
|
E
|
100 |
N
|
F
|
M
|
D
|
I
|
E
|
C
|
F
|
M
|
V
|
110 |
TM1 | |||||||||
L
|
N
|
P
|
S
|
Q
|
Q
|
L
|
A
|
I
|
A
|
120 |
V
|
L
|
S
|
L
|
T
|
L
|
G
|
T
|
F
|
T
|
130 |
V
|
L
|
E
|
N
|
L
|
L
|
V
|
L
|
C
|
V
|
140 |
ICL1 | |||||||||
I
|
L
|
H
|
S
|
R
|
S
|
L
|
R
|
C
|
R
|
150 |
TM2 | |||||||||
P
|
S
|
Y
|
H
|
F
|
I
|
G
|
S
|
L
|
A
|
160 |
V
|
A
|
D
|
L
|
L
|
G
|
S
|
V
|
I
|
F
|
170 |
V
|
Y
|
S
|
F
|
I
|
D
|
F
|
H
|
V
|
F
|
180 |
ECL1 | TM3 | ||||||||
H
|
R
|
K
|
D
|
S
|
R
|
N
|
V
|
F
|
L
|
190 |
F
|
K
|
L
|
G
|
G
|
V
|
T
|
A
|
S
|
F
|
200 |
T
|
A
|
S
|
V
|
G
|
S
|
L
|
F
|
L
|
T
|
210 |
A
|
I
|
D
|
R
|
Y
|
I
|
S
|
I
|
H
|
R
|
220 |
ICL2 | |||||||||
P
|
L
|
A
|
Y
|
K
|
R
|
I
|
V
|
T
|
R
|
230 |
TM4 | |||||||||
P
|
K
|
A
|
V
|
V
|
A
|
F
|
C
|
L
|
M
|
240 |
W
|
T
|
I
|
A
|
I
|
V
|
I
|
A
|
V
|
L
|
250 |
ECL2 | |||||||||
P
|
L
|
L
|
G
|
W
|
N
|
C
|
E
|
K
|
L
|
260 |
Q
|
S
|
V
|
C
|
S
|
D
|
I
|
F
|
P
|
H
|
270 |
TM5 | |||||||||
I
|
D
|
E
|
T
|
Y
|
L
|
M
|
F
|
W
|
I
|
280 |
G
|
V
|
T
|
S
|
V
|
L
|
L
|
L
|
F
|
I
|
290 |
V
|
Y
|
A
|
Y
|
M
|
Y
|
I
|
L
|
W
|
K
|
300 |
A
|
H
|
S
|
H
|
A
|
V
|
R
|
M
|
I
|
Q
|
310 |
ICL3 | |||||||||
R
|
G
|
T
|
Q
|
K
|
S
|
I
|
I
|
I
|
H
|
320 |
T
|
S
|
E
|
D
|
G
|
K
|
V
|
Q
|
V
|
T
|
330 |
TM6 | |||||||||
R
|
P
|
D
|
Q
|
A
|
R
|
M
|
D
|
I
|
R
|
340 |
L
|
A
|
K
|
T
|
L
|
V
|
L
|
I
|
L
|
V
|
350 |
V
|
L
|
I
|
I
|
C
|
W
|
G
|
P
|
L
|
L
|
360 |
A
|
I
|
M
|
V
|
Y
|
D
|
V
|
F
|
G
|
K
|
370 |
ECL3 | TM7 | ||||||||
M
|
N
|
K
|
L
|
I
|
K
|
T
|
V
|
F
|
A
|
380 |
F
|
C
|
S
|
M
|
L
|
C
|
L
|
L
|
N
|
S
|
390 |
T
|
V
|
N
|
P
|
I
|
I
|
Y
|
A
|
L
|
R
|
400 |
H8 | |||||||||
S
|
K
|
D
|
L
|
R
|
H
|
A
|
F
|
R
|
S
|
410 |
C-term | |||||||||
M
|
F
|
P
|
S
|
C
|
E
|
G
|
T
|
A
|
Q
|
420 |
P
|
L
|
D
|
N
|
S
|
M
|
G
|
D
|
S
|
D
|
430 |
C
|
L
|
H
|
K
|
H
|
A
|
N
|
N
|
A
|
A
|
440 |
S
|
V
|
H
|
R
|
A
|
A
|
E
|
S
|
C
|
I
|
450 |
K
|
S
|
T
|
V
|
K
|
I
|
A
|
K
|
V
|
T
|
460 |
M
|
S
|
V
|
S
|
T
|
D
|
T
|
S
|
A
|
E
|
470 |
A
|
L
|
DIAGRAMS
Pick color:
Invitro Mutant Data: Increased binding/potency: >5-fold, >10-fold; Reduced binding/potency: >5-fold, >10-fold; No/low effect (<5-fold); and N/A
Pick color:
Invitro Mutant Data: Increased binding/potency: >5-fold, >10-fold; Reduced binding/potency: >5-fold, >10-fold; No/low effect (<5-fold); and N/A
MUTATIONS
PHYSIOLOGICAL LIGANDS
2-arachidonoylglycerol, anandamide